Who we are

Alvotech is a privately owned, fully integrated specialty biopharmaceutical company focused exclusively on the development and manufacturing of high-quality biosimilar products ...

Read more



Our biosimilar assets include several biosimilar monoclonal antibodies and fusion proteins that are developed in our research & development centers located across Europe and are manufactured in our state-of-the-art facility in Reykjavik, Iceland ...

Read more


Alvotech completes enrollment of phase III study involving biosimilar version of Humira®

  • Alvotech AVT02 is developed as a high concentration (100mg/mL) formulation, expected to be more convenient for patients, differentiating from most biosimilar competitors
  • 407 participants enrolled in the Phase III study, at approximately 30 sites across Europe
  • Simultaneous Phase I PK comparability study is ongoing
  • Alvotech is also conducting related autoinjector clinical studies

Read More

Meet management

World Class team

Alvotech brings together a group of world-class pharmaceutical executives with broad backgrounds and extensive experience in the biopharmaceutical industry. The leadership team is led by Alvotech’s CEO Mark Levick and the company’s founder Robert Wessman ... 

Leadership team


Partnering with Alvotech is gaining access to high quality, ready to market biosimilars


We use cookies to ensure our website works properly and to collect statistics about users in order for us to improve the website. Learn more.